Table 2 Tumor features
From: A pilot study on the impact of known drug-drug interactions in cancer patients
Breast cancer 43 % |
Invasive ductal carcinoma (IDC): Stage II (84 %) Stage III (12 %) |
Profiles: Luminal A (48.8 %), Luminal B/HER2- (8.7 %), Luminal B/HER2+ (17.4 %), HER2+/ER- (16.0 %) and Triple Negative (7.1 %); |
Colorectal tumors 27 %: |
Adenocarcinomas, Stage IIa (25 %) Stage IIb (75 %) |
Head and neck tumors 18 % |
Larynx (Squamous), Stage I (21 %) Stage II (79 %) |
Pharynx (HPV+), Stage I (93 %) Stage II (7 %) |
Others 12 % |
Bladder (Stage I) |
Prostate (Gleason score 7) |